Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis by Post, P N et al.
Worldwide, prostate cancer has been diagnosed with increasing
frequency over recent decades (Coleman et al, 1993). This
increase is partly attributable to increased application of
transurethral resection of the prostate (TURP) (Potosky et al,
1990) for treating benign prostatic hyperplasia (BPH), which
results in the incidental detection of subclinical prostate cancer 
in approximately 10% of cases (Rohr, 1987). More recently, case
finding by prostate-specific antigen (PSA) testing has resulted in a
further increase in incidence (Potosky et al, 1995). As a conse-
quence, the prognosis for prostate cancer patients has improved in
many countries (Levi et al, 1992; Black et al, 1993; Kosary et al,
1995; Helgesen et al, 1996), reflecting the increasing proportion
detected at a preclinical stage. In south-east Netherlands, overall
5-year relative survival improved modestly from 57% in
1970–1979 to 61% in 1987–1992 (Coebergh et al, 1995); however,
the improvement occurred largely in elderly patients. The highest
increase in incidence was observed in the 1980s in the youngest
age groups in south-east Netherlands; in men under age 65 (Post et
al, 1998). As TURP is about seven times less frequently used for
men under age 60 than in men over age 75 (SIG, 1997) because of
the lower prevalence of BPH (Chute et al, 1993) and the much
lower incidence of cancer, it seemed that the increase in incidence
at younger ages might not be caused by a higher detection rate. We
studied trends in the incidence and survival of patients with
prostate cancer aged 40–59 years in south-east Netherlands and,
for comparison, in East Anglia, UK, which has a similar system of
data collection and a more or less comparable system of health
care provision. We also studied trends in mortality due to prostate
cancer and analysed changes in the distribution of grade, stage and
initial treatment. While the main study period (1971–89) was
before the introduction of PSA testing, data for 1990–1994 are
also included to provide some insight into more recent trends.
MATERIALS AND METHODS
Study population
We used data from two cancer registries, the Eindhoven Cancer
Registry in south-east Netherlands and the East Anglian Cancer
Registry in the UK. In both registries, most cases were identified
from pathology reports, which are routinely sent to the registries;
the remainder were reported by medical record departments in 
the regional hospitals and the regional radiotherapy institute
(Eindhoven) or the district general hospitals (East Anglia). South-
east Netherlands has a population of almost 1 million inhabitants
and is characterized by good access to specialized medical care
provided in eight large community hospitals. National data show
that TURP was increasingly used between 1970 and 1990 and was
the main treatment modality for both cancer of the prostate and
BPH in the 1970s. Radiotherapy was applied increasingly after
1980, but radical prostatectomy was rare. PSA assessment was not
introduced until 1990. In the Eindhoven Registry, the vital status
of all cases was determined through municipal civil registries until
1 April 1994. Five patients (2.8%) were lost to follow-up before
this date (mostly due to repeatedly moving home), and so were
censored in the analysis. East Anglia has a population of around
2.2 million inhabitants and has three specialist hospitals with
oncology centres and a further six district general hospitals. The
majority of the population lives in and around the three major
cities of Cambridge, Ipswich and Norwich, where they have good
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1991. The East Anglian Registry receives notification of the
deaths of all individuals flagged as having cancer or where cancer
is mentioned on the death certificate, from the Office of National
Statistics. In addition, it actively follows up its patients 3 years
after diagnosis and then every 5 years until death, ensuring almost
complete follow-up. Mortality data were obtained from Statistics
Netherlands and the British Office of National Statistics. The mid-
year population estimates were used for each individual year
included in the study.
Analysis
The incidence rates per 100 000 person–years for the age band
40–59 were standardized to the European Standard Population
using 5-year age-specific rates for 5-year calendar periods. As the
median survival time is approximately 5 years, we calculated the
age-standardized mortality rates for the age band 45–64 years.
Poisson regression analysis was applied to model incidence and
mortality (Clayton and Hills, 1993), using the GENMOD proce-
dure of the statistical package SAS. Significance of terms in the
models was tested with the likelihood-ratio test (Clayton and Hills,
1993). Crude and relative survival rates were calculated using the
actuarial (life table) method. Relative survival is the ratio of the
crude to the expected survival (Ederer et al, 1961). The expected
survival was calculated from life tables derived from regional
mortality statistics; data were compiled into 5-year age groups and
calendar year. A software package from the Finnish Cancer
Registry (Hakulinen and Abeywickrama, 1985) was used to calcu-
late the survival rates. The rates were adjusted for the changing
age distribution of the patient groups during the course of the
follow-up (Ederer II option). Cases identified at death were
excluded from the analyses. We used grade information as it was
registered, that is scored according to the classification of malig-
nant tumours (UICC, 1992). Information about stage was available
only in the Eindhoven Cancer Registry and only from 1980. Based
on clinical TNM assessment (UICC, 1992), we classified stages in
three  categories: small tumours confined to the prostate (T1–T2)
without evidence of metastases were classified as localized;
tumours that invaded surrounding structures (T3–T4) but without
evidence of metastases were classified as locally advanced;
patients with distant or lymph node metastases were classified as
metastasized. Grade and stage, both available from 1980, are
presented both with and without inclusion of the unknown cases.
Differences in proportions were tested with the chi-square test
(excluding unknown cases).
We classified initial treatment as TURP (including patients
detected incidentally because of TURP), hormonal treatment,
hormonal treatment after TURP and radiotherapy. Patients
receiving radiotherapy after TURP or radiotherapy and hormonal
therapy were included in the radiotherapy group. Treatment infor-
mation was available for the period 1971–89 in the Eindhoven
Registry and from 1980 to 1989 in East Anglia.
RESULTS
The number of patients aged 40–59 diagnosed with prostate cancer
between 1971 and 1989 was 181 in south-east Netherlands and
384 in East Anglia, being 7% and 4% respectively of patients at all
ages with prostate cancer diagnosed between 1971 and 1989. The
proportion of patients with a histologically confirmed diagnosis at
ages 40–59 was more than 95% during the whole study period in
both populations.
Between 1971 and 1989, the age-adjusted incidence rate for
men aged 40–59 increased from 8.8 per 105 to 12.5 per 105 in
south-east Netherlands and from 7.0 per 105 to 11.6 per 105 in East
Anglia (Figure 1). The mean age at diagnosis of the patients in this
age group barely changed over the study period, being 55.4 years
in The Netherlands and 55.6 in East Anglia. A multivariate model
for the incidence up to 1994 was fitted that included age group,
registry and calendar period [deviance 35.0, 34 degrees of freedom
(d.f.)]. The risk ratio of the incidence increased for each subse-
quent period up to 1990–94 (Table 1). The test for trend was
significant (P = 0.0001) and the trend was similar in both
registries. A similar result was obtained when the period 1990–94
was excluded. The age-standardized mortality rate for prostate
cancer among men aged 45–64 years increased between 1971 and
1989 from 7.4 to 11.1 per 105 in south-east Netherlands and from
7.5 to 12.1 per 105 in East Anglia. A model was built including age
group, calendar period and registry (deviance 47.1, 34 d.f.). The
risk ratio increased with each subsequent period up to 1985–89,
followed by a slight decline in 1990–94 (Table 1). Nevertheless,
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Figure 1 Incidence rates per 100 000 person–years standardized to the
European standard population (A) and 5-year relative survival rates (B) for
prostate cancer patients aged 40–59 in south-east Netherlands (n) and East
Anglia (s)
Incidence
% survivalthe test for trend was significant (P = 0.0001) and the trend was
similar in both registries.
In south-east Netherlands, 5-year relative survival improved
slightly in the early 1970s, but declined from 65% (95% CI 47–83)
in 1975–79 to 48% (CI 34–62) in 1985–89 (Figure 1). In East
Anglia, 5-year relative survival was initially considerably lower,
being 48% (CI 34–62) in 1971–74 and decreasing slightly to 46%
(CI 36–56) in 1985–89. The crude survival followed a similar trend.
In spite of an increase in the estimated proportion of patients
with localized cancer from 47% in 1980–84 to 56% in 1985–89 in
south-east Netherlands (Table 2), the estimated proportion of
patients with poorly differentiated tumours increased from 15% to
25% (Table 3). The proportion of patients aged 40–59 years
receiving radiotherapy increased from 21% in 1975–79 to 55% in
1985–89 in south-east Netherlands and radiotherapy has also been
the main treatment modality in East Anglia between 1980 and
1989 (Table 4). The remainder of patients received endocrine
therapy or TURP. Radical prostatectomy was only rarely applied
before 1990 in both populations.
DISCUSSION
We report a similar rise in the incidence of prostate cancer among
men aged 40–59 years in south-east Netherlands and East Anglia
and no improvement in prognosis in the period preceding the intro-
duction of PSA testing in 1990. Improved diagnosis does not seem
to be an important factor in the rise in incidence because it would
have resulted in the inclusion of more non-aggressive cases and,
thus, in improved survival. Moreover, in spite of a more
favourable stage distribution, we did not observe an increase in
well-differentiated tumours in this period.
Our findings are conditional on the accuracy of the two cancer
registries. Comparisons with mortality data and analysis of referral
patterns indicate that both registries can be considered virtually
complete for prostate cancer as of 1971 and both comply with the
standards of the International Agency for Research on Cancer
(Parkin et al, 1992). Few patients were lost to follow-up, so that
selective loss is not likely to be an issue. The study populations
were relatively small, especially in south-east Netherlands, but our
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Table 1 Risk ratios and 95% confidence intervals for incidence (40–59 years) of and mortality (45–64 years) due to
prostate cancer in south-east Netherlands and East Anglia
Incidence (40–59 years) Mortality (45–64 years)
Risk ratio (95% Cl) No. of cases Risk ratio (95% Cl) No. of cases
1971–74 (reference) 1 82 1 82
1975–79 1.11 (0.84–1.47) 127 1.02 (0.77–1.36) 108
1980–84 1.33 (1.02–1.73) 162 1.24 (0.95–1.63) 140
1985–89 1.53 (1.19–1.99) 194 1.63 (1.26–2.12) 195
1990–94 1.91 (1.49–2.46) 255 1.53 (1.18–1.98) 191
P-value trend 0.0001 0.0001
Table 2 Trend in stage distribution (%) (with and without unknown cases) of
prostate cancer patients aged 40–59 in south-east Netherlands, 1980–94
1980–84 1985–89 1990–94
n 51 65 108
% within period % %
Stage
Localized 40 53 57
Locally advanced 8 12 12
Metastasized 39 29 18
Unknown 13 6 13
Stage
Localized 47 56 66
Locally advanced 9 13 13
Metastasized 44 31 21
P-value c2 0.07
Table 3 Trend in grade distribution (%) (with and without unknown cases) of prostate cancer patients
aged 40–59 in south-east Netherlands and East Anglia, 1980–94
South-east Netherlands East Anglia
1980–84 1985–89 1990–94 1980–84 1985–89 1990–94
n 51 65 108 111 129 147
% within % % % % %
period
Differentiation
Well 36 34 41 24 22 25
Moderately 31 37 31 18 24 29
Poorly 12 23 22 18 21 22
Unknown 20 6 6 40 33 24
Differentiation
Well 46 36 44 40 33 33
Moderately 39 39 33 30 36 38
Poorly 15 25 23 30 31 29
P-value c2 0.6 P > 0.1findings are not compatible with a significant improvement in
survival. Moreover, registry-based studies in other countries have
provided similar results. In Sweden, 5-year relative survival for
prostate cancer patients aged 45–54 years improved from 42% in
the early 1960s to 62% in the late 1970s but declined to 50% in the
early 1980s (Helgesen et al, 1996). In Scotland, it declined from
47% in 1978–82 to 32% in 1983–87 (Black et al, 1993). In
Switzerland (Vaud), the relative survival for patients aged under
60 only improved slightly from 39% in 1974–78 to 41% in
1979–83 (Levi et al, 1992), which was similar to the situation for
Finnish patients (Dickman et al, 1998). We do not know why the
prognosis barely changed in East Anglia but deteriorated in south-
east Netherlands. A lower level of access to specialized care may
have played a role in the initially lower survival in East Anglia,
because the Eurocare study showed that similar differences in
survival existed between south-east Netherlands and Great Britain
for patients with lung, breast or colorectal cancer, which may be
related to differences in stage at diagnosis (Berrino et al, 1995).
Increasing awareness of prostate cancer and early diagnosis was
probably not apparent before 1980 in East Anglia.
Our hypothesis, that a genuine increase in incidence has
occurred, is also supported by the increase in mortality attributable
to prostate cancer under 65 years, which was similar in both popu-
lations, although it was followed by a small decline in 1990–94.
An analysis of national mortality data from 1950–89 showed an
increase in mortality due to prostate cancer in consecutive birth
cohorts of men born around 1925 in The Netherlands (Van der
Gulden et al, 1994). In Norway, the increase in both incidence and
mortality due to prostate cancer between 1957 and 1991 was
highest in men under 60 years (Harvei et al, 1996). In the USA,
mortality due to prostate cancer has started to decline since
1991–95, in particular for men under age 75 (Hoeksema and Law,
1996), whereas it had increased slightly in those under age 65 in
the years beforehand (Kosary et al, 1995). The decline, however,
may be related to the widespread introduction of early detection
and intervention techniques. Changes in cause-specific mortality
such as that observed for cancer of the prostate in Eindhoven and
East Anglia should be interpreted with caution. All-cause
mortality has also been declining in both populations for the age
group studied. In particular, mortality attributable to cardiovas-
cular causes declined in The Netherlands from 499 per 105 in 1970
to 301 per 105 in 1990 for men aged 45–64 years (Central Bureau
of Statistics, 1992). As a result of the decrease in concurrent
causes of death, the probability that prostate cancer was recorded
as the cause of death may have increased. However, this explana-
tion would be more plausible for mortality in older age groups.
We suggest, therefore, that an increased risk of prostate cancer
in those under age 60 has almost certainly occurred over the
period 1971 to 1989. As far as we know, only one aetiological
study has focused on the under 60 age group, reporting a relative
risk (RR) of 1.9 for cigarette smoking, a RR of 1.4 for vasectomy
and a RR of 2.3 for early age at first sexual intercourse (Honda et
al, 1988). Recently, Rodriguez et al (1997) reported a significant
association of current smoking with fatal prostate cancer (RR
1.34), which was highest among men below 60 years (RR 1.83),
but there was no association with the number of cigarettes smoked
or with the duration of smoking at baseline for the cohort in 1982.
Nor was there any increased risk for former smokers (Rodriguez et
al, 1997). This, as well as results from other large studies, suggests
that smoking may adversely influence survival in prostate cancer
patients. Increased occurrence of a factor associated with a worse
survival could be an alternative explanation for our findings.
However, smoking is not a likely candidate, because the propor-
tion of male smokers decreased markedly from 95% in 1960 to
40% in 1981 in The Netherlands (Janssen-Heijnen et al, 1995) and
also in England (Coleman et al, 1993).
Unfavourable changes in the health care system do not seem to
play a role, because the proportion of cases detected at an earlier
stage increased over the study period, at least in south-east
Netherlands. Furthermore, radiotherapy was applied increasingly
during the study period. Although a beneficial effect of radio-
therapy on survival has not been proven definitively (Lu-Yao and
Yao, 1997), it seems unlikely that radiotherapy has been detri-
mental for prostate cancer patients. We, therefore, assume that
increased incidence of fatal prostate cancer, of which the cause
still needs to be unravelled, should explain our findings.
Although the incidence continued to increase, mortality due to
prostate cancer decreased slightly in the 1990s. This could mean
that the postulated genuine increase in incidence has come to a
halt in the 1990s. Continuing studies of incidence and survival
may provide more insight into the nature of the most recent
increase in incidence.
From the current study, we conclude that increased detection
of prostate cancer by TURP cannot explain the considerable
increase in incidence between 1971 and 1989 in the age group
below 60 years.
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Table 4 Trend in initial treatment (%) of prostate cancer patients aged 40–59 in
south-east Netherlands and East Anglia
1971–74 1975–79 1980–84 1985–89
Eindhoven
Radiotherapy 0 21 38 55
Endocrine therapy 32 24 4 22
Endocrine + TURP 36 7 13 9
TURP 28 48 40 14
None 4 5
East Anglia
Radiotherapy 42 46
Endocrine therapy 12 6
Endocrine + TURP 15 15
TURP 26 26
None/Unknown 5 7ACKNOWLEDGEMENTS
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